JP2014520877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520877A5 JP2014520877A5 JP2014520691A JP2014520691A JP2014520877A5 JP 2014520877 A5 JP2014520877 A5 JP 2014520877A5 JP 2014520691 A JP2014520691 A JP 2014520691A JP 2014520691 A JP2014520691 A JP 2014520691A JP 2014520877 A5 JP2014520877 A5 JP 2014520877A5
- Authority
- JP
- Japan
- Prior art keywords
- pml
- protein
- subject
- group
- jcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 230000001506 immunosuppresive effect Effects 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 10
- 206010061598 Immunodeficiency Diseases 0.000 claims description 8
- 229960005027 natalizumab Drugs 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 6
- 206010025327 Lymphopenia Diseases 0.000 claims description 5
- 229960000548 alemtuzumab Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229960000284 efalizumab Drugs 0.000 claims description 5
- 231100001023 lymphopenia Toxicity 0.000 claims description 5
- 229950005751 ocrelizumab Drugs 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 229940124614 TLR 8 agonist Drugs 0.000 claims description 4
- 229960002751 imiquimod Drugs 0.000 claims description 4
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 claims description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 208000031957 HIV carrier Diseases 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- HACHPVCYFLSKSB-UMJDSZQGSA-N ManNAz-DBCO-Pam3CSK4 Chemical compound CCCCCCCCCCCCCCCC(N[C@H](CSCC(COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)C(N[C@H](CO)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(NCCC(N(C1)C2=CC=CC=C2C2N(C(N[C@H]([C@H](C3)O)[C@H]([C@@H]([C@@H](CO)O)O)O[C@@]3(C(O)=O)O)=O)N=NC2C2=C1C=CC=C2)=O)=O)=O)=O)=O)=O)=O)=O HACHPVCYFLSKSB-UMJDSZQGSA-N 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 108700003135 N-acetylglucosamine-N-acetylmuramyl-alanyl-isoglutaminyl-alanyl-glycerol dipalmitoyl Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- DNUXJWBKTMJNEP-JVSLBXKQSA-N [(2R)-3-[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,6-dihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]([C@@H](NC(C)=O)C=O)[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@H](O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC DNUXJWBKTMJNEP-JVSLBXKQSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 229940124669 imidazoquinoline Drugs 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical group CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 claims description 2
- -1 stearyl tyrosine Chemical compound 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000969 carrier Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006031A EP2548567A1 (en) | 2011-07-22 | 2011-07-22 | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications |
| EP11006031.6 | 2011-07-22 | ||
| PCT/EP2012/064445 WO2013014134A2 (en) | 2011-07-22 | 2012-07-23 | Polyoma virus jc peptides and proteins in vaccination and diagnostic applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520877A JP2014520877A (ja) | 2014-08-25 |
| JP2014520877A5 true JP2014520877A5 (cg-RX-API-DMAC7.html) | 2015-09-10 |
Family
ID=46548481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520691A Pending JP2014520877A (ja) | 2011-07-22 | 2012-07-23 | ワクチン接種および診断適用におけるポリオーマウイルスjcペプチドおよびタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9738690B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2548567A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014520877A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140062702A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103826653A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012288955B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014001516A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2842543A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201490322A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1198517A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014000776A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013014134A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150065367A1 (en) * | 2011-12-12 | 2015-03-05 | Janssen Diagnostics Bvba | Polyomavirus peptide sequences |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| US9931393B2 (en) | 2013-12-20 | 2018-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic JC polyomavirus compositions and methods of use |
| EP2926831A1 (en) * | 2014-03-31 | 2015-10-07 | Ruprecht-Karls-Universität Heidelberg | CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination |
| WO2016073595A1 (en) * | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| WO2016104046A1 (ja) * | 2014-12-22 | 2016-06-30 | 日東電工株式会社 | 透明導電性フィルム |
| IT201600083859A1 (it) * | 2016-08-09 | 2018-02-09 | Univ Degli Studi Di Ferrara | Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici. |
| CN113278634B (zh) | 2020-11-16 | 2022-06-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3767755B2 (ja) | 1995-06-23 | 2006-04-19 | エーザイ株式会社 | 抗jcウイルス抗体 |
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| DE10131145B4 (de) | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| JP4840792B2 (ja) | 2001-11-22 | 2011-12-21 | 独立行政法人科学技術振興機構 | JCウイルスagnoを対象としたPMLの治療 |
| AU2003238008A1 (en) | 2002-06-12 | 2003-12-31 | Temple University Of The Commonwealth System Of Higher Education | Method of cell growth inhibition with agnoprotein |
| JP2005341864A (ja) | 2004-06-02 | 2005-12-15 | Japan Science & Technology Agency | Jcウイルスの粒子形成阻害剤 |
| US7468186B2 (en) * | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| US20080057079A1 (en) | 2006-08-31 | 2008-03-06 | Baylor Research Institute | JC Virus Vaccine |
| CN100595765C (zh) * | 2008-06-30 | 2010-03-24 | 腾讯科技(深圳)有限公司 | 基于媒体播放器的关键词内容发布方法及系统 |
| AU2010210979B2 (en) * | 2009-02-05 | 2015-12-10 | Biogen Ma Inc. | Methods for the detection of JC polyoma virus |
| WO2010099205A1 (en) | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
| EP2226392A1 (en) * | 2009-03-03 | 2010-09-08 | Assistance Publique - Hôpitaux de Paris | Method for detecting JCV infection |
| WO2011124652A1 (en) * | 2010-04-08 | 2011-10-13 | Fondazione Centro San Raffaele Del Monte Tabor | Immunodominant peptide of polyomavirus jc and uses thereof |
-
2011
- 2011-07-22 EP EP11006031A patent/EP2548567A1/en not_active Withdrawn
-
2012
- 2012-07-23 EP EP12737822.2A patent/EP2734218A2/en not_active Withdrawn
- 2012-07-23 EA EA201490322A patent/EA201490322A1/ru unknown
- 2012-07-23 KR KR1020147004608A patent/KR20140062702A/ko not_active Withdrawn
- 2012-07-23 US US14/234,065 patent/US9738690B2/en not_active Expired - Fee Related
- 2012-07-23 WO PCT/EP2012/064445 patent/WO2013014134A2/en not_active Ceased
- 2012-07-23 JP JP2014520691A patent/JP2014520877A/ja active Pending
- 2012-07-23 MX MX2014000776A patent/MX2014000776A/es unknown
- 2012-07-23 HK HK14112523.5A patent/HK1198517A1/xx unknown
- 2012-07-23 CN CN201280041815.3A patent/CN103826653A/zh active Pending
- 2012-07-23 AU AU2012288955A patent/AU2012288955B2/en not_active Expired - Fee Related
- 2012-07-23 CA CA2842543A patent/CA2842543A1/en not_active Abandoned
- 2012-07-23 BR BR112014001516A patent/BR112014001516A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akbari et al. | Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia | |
| US10722562B2 (en) | Combinatorial analysis and repair | |
| Martins et al. | Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity | |
| JP2014534202A5 (cg-RX-API-DMAC7.html) | ||
| EP3851120A1 (en) | Immunogen for broad-spectrum influenza vaccine and application thereof | |
| JP2011250797A5 (cg-RX-API-DMAC7.html) | ||
| JP2018523668A5 (cg-RX-API-DMAC7.html) | ||
| Baydemir et al. | Trained immunity-inducing vaccines: Harnessing innate memory for vaccine design and delivery | |
| WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| JP2019520061A5 (cg-RX-API-DMAC7.html) | ||
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| JP2021169495A (ja) | 酵母細胞壁粒子を用いたワクチン送達系 | |
| Helou et al. | Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis | |
| JP2015514115A5 (cg-RX-API-DMAC7.html) | ||
| JP2014139185A5 (cg-RX-API-DMAC7.html) | ||
| AU2012288955A1 (en) | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications | |
| JP2006502228A5 (cg-RX-API-DMAC7.html) | ||
| Esposito et al. | Herpes zoster prevention: a difficult problem to solve | |
| RU2014140731A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| JP2017516752A5 (cg-RX-API-DMAC7.html) | ||
| Maurya et al. | Novel stem cells and nucleic acid-based vaccine trials against viral outbreak: a systematic evaluation during COVID-2019 pandemic | |
| Semakova et al. | Adjuvant technologies in the construction of advanced vaccines | |
| Płaszczyńska et al. | Regression of common viral warts after ChAdOx1‐S COVID‐19 vaccine | |
| JP2017502058A5 (cg-RX-API-DMAC7.html) | ||
| O’Shea et al. | Changing face of vaccination in immunocompromised hosts |